Summary
Thermo Fisher Scientific Inc. (TMO) filed its amended Annual Report (10-K/A) for the fiscal year ended December 31, 2014, on March 4, 2015. The primary purpose of this amendment was to correct a table within the "Results of Operations" section, with no other changes to the original filing. The report highlights a significant year driven by the acquisition of Life Technologies for $15.30 billion, which substantially boosted revenues and expanded the Life Sciences Solutions segment. Despite substantial integration costs and amortization related to the acquisition, Thermo Fisher demonstrated robust performance, with total revenues increasing by $3.80 billion year-over-year, reaching $16.89 billion. Operating income and margin also saw substantial improvements, largely attributable to the Life Technologies acquisition and gains from strategic divestitures. Investors should note the company's active M&A strategy, as evidenced by the Life Technologies acquisition and subsequent divestitures of non-core assets. The company also completed the sale of its Cole-Parmer specialty channel business. Management expressed confidence in the company's liquidity and ability to meet future cash requirements through existing cash, operational cash flow, and available credit facilities, despite facing some short-term debt obligations. The report also touches upon critical accounting policies, particularly concerning business combinations, intangible assets, and goodwill, reflecting the complexities introduced by recent acquisitions.
Financial Highlights
59 data points| Revenue | $16.89B |
| Cost of Revenue | $7.93B |
| Gross Profit | $8.95B |
| R&D Expenses | $691.10M |
| SG&A Expenses | $4.90B |
| Operating Expenses | $14.39B |
| Operating Income | $2.50B |
| Interest Expense | $479.90M |
| Net Income | $1.89B |
| EPS (Basic) | $4.76 |
| EPS (Diluted) | $4.71 |
| Shares Outstanding (Basic) | 398.20M |
| Shares Outstanding (Diluted) | 402.30M |
Key Highlights
- 1In 2014, Thermo Fisher Scientific completed the significant acquisition of Life Technologies for $15.30 billion, a move that substantially reshaped its business and revenue streams, particularly within the Life Sciences Solutions segment.
- 2Total revenues for 2014 reached $16.89 billion, an increase of $3.80 billion from 2013, driven primarily by acquisitions (+$3.31 billion net of divestitures) and organic growth (+$549 million or 4%).
- 3Operating income significantly improved to $2.50 billion in 2014 from $1.61 billion in 2013, with the operating margin increasing from 12.3% to 14.8%, benefiting from the Life Technologies integration and business divestiture gains.
- 4Strategic divestitures of non-core assets, including the legacy sera and media business (to GE Healthcare for $1.06 billion) and the Cole-Parmer specialty channel business (for $480 million), were completed to streamline operations and secure antitrust approval for the Life Technologies acquisition.
- 5The company maintained a strong liquidity position, with $1.35 billion in cash and short-term investments as of December 31, 2014, and ample borrowing capacity under its revolving credit facility, which was increased to $2.00 billion in February 2015.
- 6Despite a substantial increase in interest expense due to debt raised for the Life Technologies acquisition, the company reported a strong increase in income from continuing operations to $1.90 billion in 2014 from $1.28 billion in 2013.